Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Read Our Latest Stock Report on VERX Vertex Stock Down 3.3 % Shares of NASDAQ:VERX opened at $32.88 on Friday. The stock has a market capitalization of $5.13 billion, a P/E ratio of 182.67, a PEG ...

Boston is considered a top-heavy system, and four players are in MLB.com's top 100 rankings, led by elite outfield prospect Roman Anthony. Meanwhile, according to Baseball America and Baseball ...

Boston Scientific’s $664m bet on Bolt Medical has paid off, as the company’s intravascular lithotripsy (IVL) system gains US Food and Drug Administration (FDA) clearance. Whilst neither Bolt ...

Vertex holds a dominant position in the cystic franchise (“CF”) market. Its CF sales continue to grow, driven by higher sales of Trikafta/Kaftrio in younger age groups. Vertex’s CF product ...

Journavx halts pain signaling in the peripheral nervous system before these signals get to the brain. And since the drug works outside of the brain, it isn't associated with addiction. Vertex ...

Reporter Mandy McLaren’s article highlights just one example of how a flawed system promotes conflict rather than collaboration. Special education funding is often considered a zero-sum game ...

In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.

The biotech's interim CEO is a board member who was a former top executive at Vertex Pharmaceuticals who ... medical school in Chicago and came to Boston for pediatric neurology training, he ...

Fans will be able to access Formula One tickets on viagogo through BWT Alpine Formula One Team’s partnership with the world’s leading ticketing marketplace. LONDON--(BUSINESS WIRE)--BWT Alpine ...

DP_Boston 2, Baltimore 0. LOB_Boston 5, Baltimore 6. 2B_Bregman 2 (2), Kjerstad (1), Mountcastle (2), Holliday (1). HR_Bregman (1), Campbell (2), Casas (1), Mullins ...

Despite some notable successes, including US approval in January of a nonopioid painkiller by Boston biotech Vertex, there are few signs the industry — responsible for more than 115,000 ...